title: Visual field improvement in the collaborative initial glaucoma treatment study.
abstract: OBJECTIVE
  To evaluate critically visual field (VF) improvement in participants in the Collaborative Initial Glaucoma Treatment Study (CIGTS).
  
  
  METHODS
  Prospective, comparative case series from a randomized clinical trial comparing trabeculectomy and topical medications in treating open-angle glaucoma (OAG).
  
  
  METHODS
  A total of 607 subjects with newly diagnosed OAG were identified for study. Baseline and follow-up VF tests were obtained and mean deviation (MD) change from baseline over follow-up was analyzed. Clinically substantial change (loss or improvement) was defined as change from baseline of ≥ 3 decibels in MD. Baseline factors were inspected to determine their association with VF improvement in repeated measures regression models.
  
  
  RESULTS
  The percentage of participants showing substantial VF improvement over time was similar to that showing VF loss through 5 years after initial treatment, after which VF loss became more frequent. Measures of better intraocular pressure (IOP) control during treatment were significantly predictive of VF improvement, including a lower mean IOP, a lower minimum IOP, and lower sustained levels of IOP over follow-up. Other predictive factors included female sex (odds ratio [OR] = 1.73), visits 1 year prior to cataract extraction (OR = 0.11), and an interaction between treatment and baseline MD wherein surgically treated subjects with worse baseline VF loss were more likely to show VF improvement.
  
  
  CONCLUSIONS
  In the CIGTS, substantial VF loss and improvement were comparable through 5 years of follow-up, after which VF loss became more frequent. Predictive factors for VF improvement included several indicators of better IOP control, which supports the postulate that VF improvement was real.
authors.affiliation: Department of Ophthalmology and Visual Sciences, Medical School, University of Michigan, Ann Arbor, Michigan; Department of Epidemiology, School of Public Health, University of Michigan, Ann Arbor, Michigan. Electronic address: dmusch@med.umich.edu.
authors.forename: David C
authors.initials: DC
authors.lastname: Musch
authors.affiliation: Department of Biostatistics, School of Public Health, University of Michigan, Ann Arbor, Michigan.
authors.forename: Brenda W
authors.initials: BW
authors.lastname: Gillespie
authors.affiliation: Bascom Palmer Eye Institute, University of Miami, Miami, Florida.
authors.forename: Paul F
authors.initials: PF
authors.lastname: Palmberg
authors.affiliation: Wills Eye Hospital, Philadelphia, Pennsylvania.
authors.forename: George
authors.initials: G
authors.lastname: Spaeth
authors.affiliation: Department of Ophthalmology and Visual Sciences, Medical School, University of Michigan, Ann Arbor, Michigan.
authors.forename: Leslie M
authors.initials: LM
authors.lastname: Niziol
authors.affiliation: Department of Ophthalmology and Visual Sciences, Medical School, University of Michigan, Ann Arbor, Michigan.
authors.forename: Paul R
authors.initials: PR
authors.lastname: Lichter
mesh_terms: D000328:Adult; D000368:Aged; D000959:Antihypertensive Agents / Q000627:therapeutic use*; D005260:Female; D005500:Follow-Up Studies; D005902:Glaucoma, Open-Angle / Q000503:physiopathology / Q000628:therapy*; D006801:Humans; D007429:Intraocular Pressure / Q000502:physiology; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D014130:Trabeculectomy; D014786:Vision Disorders / Q000503:physiopathology*; D014792:Visual Acuity / Q000502:physiology; D058609:Visual Field Tests; D014794:Visual Fields / Q000502:physiology*
chemical_list: D000959:Antihypertensive Agents
references.citation: Br J Ophthalmol. 2003 Jan;87(1):107-12
references.pmid: 12488273
references.citation: Ophthalmology. 2011 Sep;118(9):1766-73
references.pmid: 21600658
references.citation: Int J Epidemiol. 2005 Feb;34(1):215-20
references.pmid: 15333621
references.citation: Biometrics. 1988 Dec;44(4):1049-60
references.pmid: 3233245
references.citation: Acta Ophthalmol (Copenh). 1991 Apr;69(2):210-6
references.pmid: 1872140
references.citation: Ophthalmology. 2009 Feb;116(2):200-7
references.pmid: 19019444
references.citation: Optom Vis Sci. 2008 Nov;85(11):1043-8
references.pmid: 18981919
references.citation: Invest Ophthalmol Vis Sci. 2013 Dec 13;54(14):ORSF60-7
references.pmid: 24335071
references.citation: Am J Ophthalmol. 1989 May 15;107(5):485-92
references.pmid: 2712131
references.citation: Ophthalmology. 1996 Jan;103(1):186-9
references.pmid: 8628553
references.citation: Ophthalmology. 1999 Apr;106(4):653-62
references.pmid: 10201583
references.citation: Control Clin Trials. 1994 Aug;15(4):299-325
references.pmid: 7956270
references.citation: Arch Ophthalmol. 1999 May;117(5):573-83
references.pmid: 10326953
references.citation: Trans Ophthalmol Soc U K. 1985;104 ( Pt 3):256-64
references.pmid: 3861005
references.citation: Invest Ophthalmol Vis Sci. 2003 Jun;44(6):2613-20
references.pmid: 12766064
references.citation: Am J Ophthalmol. 2002 Sep;134(3):399-405
references.pmid: 12208252
references.citation: Arch Ophthalmol. 1996 Jan;114(1):19-22
references.pmid: 8540846
references.citation: Am J Ophthalmol. 2009 Apr;147(4):717-724.e1
references.pmid: 19152871